개 CD137 / 4-1BB / TNFRSF9 단백질 (His 태그)

  • Canine CD137 / 4-1BB / TNFRSF9 Protein (His Tag) SDS-PAGE
데이터시트리뷰관련제품프로토콜
 4-1BB/TNFRSF9 단백질 제품 정보
동의어:TNFRSF9
단백질 구조:A DNA sequence encoding the canine TNFRSF9 (XP_850336.1) (Met1-Ser185) was expressed with a C-terminal polyhistidine tag.
:Canine
발현 숙주:Human Cells
양식 및 배송:In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
 4-1BB/TNFRSF9 단백질 품질 관리 검사
순도:> 95 % as determined by SDS-PAGE
생리활성:Measured by its binding ability in a functional ELISA.
Immobilized canine TNFRSF9-His at 10 μg/ml (100 μl/well) can bind rat Fc-TNFSF9 (Cat:80166-R01H), The EC50 of rat Fc-TNFSF9 (Cat:80166-R01H) is 0.26-0.62 μg/ml.
내독소:< 1.0 EU per μg of the protein as determined by the LAL method
안정성:Samples are stable for up to twelve months from date of receipt at -70℃
예상된 N 말단(N Terminal):Ile 24
분자량:The recombinant canine TNFRSF9 comprises 173 amino acids and has a predicted molecular mass of 18.4 kDa. The apparent molecular mass of the protein is approximately 28-34 kDa in SDS-PAGE under reducing conditions due to glycosylation.
Formulation:Lyophilized from sterile PBS, pH 7.4.
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
2. Please contact us for any concerns or special requirements.
 4-1BB/TNFRSF9 단백질 사용 가이드
보관:Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
복원:A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
 4-1BB/TNFRSF9 Protein SDS-PAGE
Canine CD137 / 4-1BB / TNFRSF9 Protein (His Tag) SDS-PAGE
Other 4-1BB/TNFRSF9 Recombinant Protein Products
70095-D08H
4-1BB/TNFRSF9/CD137 연구배경

CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials.

Immune Checkpoint
Immune Checkpoint Detection: Antibodies   Immune Checkpoint Detection: ELISA Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets   Co-stimulatory Immune Checkpoint Targets

Immunotherapy   Cancer Immunotherapy   Targeted Therapy

 4-1BB/TNFRSF9/CD137 참고자료
  • Sica G, et al. (1999) Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy. Arch Immunol Ther Exp (Warsz). 47(5): 275-9.
  • Nam KO, et al. (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets. 5(5): 357-63.
  • Wang Q, et al. (2008) Analysis of CD137 and CD137L expression in human primary tumor tissues. Croat Med J. 49(2): 192-200.
  • Melero I, et al. (2008) Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci. 29(8): 383-90.
  • Thum E, et al. (2009) CD137, implications in immunity and potential for therapy. Front Biosci. 14: 4173-88.
  • Product nameProduct name
    Size / Price
    Cat No: 70095-D08H-100
    정가: 
    가격:      (You Save: )

    Datasheet & Documentation

    Contact Us
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    주의 : 모든 제품은 "연구 목적만을 위한 것이며 진단이나 치료에 사용하도록 의도되지 않았습니다".